Business description: Viyash Scientific Limited

SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. The Company’s subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.

Number of employees: 1,244

Sales by Activity: Viyash Scientific Limited

Fiscal Period: March 2021 (INR) 2022 (INR) 2023 (INR) 2024 (INR) 2025 (INR)

Pharmaceuticals

13.62B 14.13B 14.21B 13.7B 15.51B

Geographical breakdown of sales: Viyash Scientific Limited

Fiscal Period: March 2021 (INR) 2022 (INR) 2023 (INR) 2024 (INR) 2025 (INR)

Europe

6.25B 5.94B 5.76B 5.72B 7B

Asia

3.89B 3.9B 4.76B 3.3B 4.45B

Rest of the World

3.48B 4.29B 3.69B 4.68B 4.06B

Executive Committee: Viyash Scientific Limited

Manager TitleAgeSince
Chief Executive Officer 62 2025-12-15
Compliance Officer - 2024-12-16
Chief Administrative Officer - 2013-12-31
Chief Tech/Sci/R&D Officer - 2018-12-31
Chief Executive Officer 57 2022-04-10

Composition of the Board of Directors: Viyash Scientific Limited

Director TitleAgeSince
Chairman 78 -
Director/Board Member 66 2020-08-24
Director/Board Member 65 2020-11-05
Director/Board Member 64 2020-12-13
Director/Board Member 57 2022-04-10
Director/Board Member 62 2023-08-06
Director/Board Member 51 2025-09-04
Director/Board Member - 2025-12-15

Shareholders: Viyash Scientific Limited

NameEquities%Valuation
The Carlyle Group LP (Global Private Equity)
61.34 %
267,840,334 61.34 % 626 M ₹
quant Money Managers Ltd.
5.675 %
24,777,412 5.675 % 58 M ₹
Ashoka Whiteoak Capital Pte Ltd.
0.8461 %
3,694,299 0.8461 % 9 M ₹
UTI Asset Management Co. Ltd. (Investment Management)
0.2505 %
1,093,865 0.2505 % 3 M ₹
Motilal Oswal Asset Management Co. Ltd.
0.113 %
493,255 0.113 % 1 M ₹

Company details: Viyash Scientific Limited

SeQuent Scientific Ltd.

301/A, Dosti Pinnacle

400604, Mumbai

+91 22 4111 4777

http://www.sequent.in
address Viyash Scientific Limited(VIYASH)

Group companies: Viyash Scientific Limited

NameCategory and Sector
Pharmaceuticals: Major
Pharmaceuticals: Major
Pharmaceuticals: Major
Drugstore Chains

Other Pharmaceuticals

Change 5d. change 1-year change 3-years change Capi.($)
0.00%-3.57%+43.25%+165.82% 924M
+0.80%-0.53%+22.88%+203.58% 880B
-0.21%+0.47%+48.18%+57.79% 582B
-2.52%-4.53%+3.84%+44.57% 388B
+0.79%-6.01%+5.81%+21.36% 324B
+0.11%-0.83%+21.02%+34.57% 295B
+0.43%-1.54%+25.20%+62.42% 293B
-0.26%-0.16%+22.07%+9.34% 286B
-0.43%-0.90%+17.13%+57.05% 197B
+0.42%+0.74%+27.91%+82.35% 180B
Average -0.26%-1.69%+23.73%+73.89% 342.71B
Weighted average by Cap. -0.38%-1.37%+23.31%+85.91%
  1. Stock Market
  2. Equities
  3. VIYASH Stock
  4. Company Viyash Scientific Limited
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW